Wedbush Decreases Earnings Estimates for Ascendis Pharma A/S

Ascendis Pharma A/S (NASDAQ:ASND) – Analysts at Wedbush dropped their FY2027 earnings per share estimates for shares of Ascendis Pharma A/S in a research note issued to investors on Thursday, January 16th. Wedbush analyst Y. Zhong now anticipates that the biotechnology company will post earnings of $3.37 per share for the year, down from their previous estimate of $3.59. Wedbush currently has a “Outperform” rating and a $181.00 target price on the stock. The consensus estimate for Ascendis Pharma A/S’s current full-year earnings is ($7.43) per share. Wedbush also issued estimates for Ascendis Pharma A/S’s FY2028 earnings at $8.78 EPS.

Several other equities analysts have also weighed in on the stock. UBS Group assumed coverage on shares of Ascendis Pharma A/S in a research report on Tuesday, January 7th. They issued a “buy” rating and a $196.00 price objective on the stock. Bank of America increased their price target on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a “buy” rating in a report on Monday, September 23rd. StockNews.com upgraded Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. TD Cowen lowered their target price on Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating on the stock in a research note on Friday, November 15th. Finally, Stifel Nicolaus lifted their price target on Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a “buy” rating in a report on Friday, November 15th. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $192.07.

Ascendis Pharma A/S Price Performance

Shares of Ascendis Pharma A/S stock opened at $128.13 on Monday. The business has a fifty day simple moving average of $133.12 and a two-hundred day simple moving average of $133.43. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $161.00. The company has a market capitalization of $7.78 billion, a price-to-earnings ratio of -15.86 and a beta of 0.65.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Wilmington Savings Fund Society FSB acquired a new position in shares of Ascendis Pharma A/S in the 3rd quarter valued at approximately $30,000. GAMMA Investing LLC increased its stake in Ascendis Pharma A/S by 58.0% in the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock valued at $80,000 after acquiring an additional 214 shares during the last quarter. Signaturefd LLC increased its stake in Ascendis Pharma A/S by 13.2% in the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock valued at $102,000 after acquiring an additional 80 shares during the last quarter. Pursue Wealth Partners LLC bought a new stake in Ascendis Pharma A/S during the third quarter worth $217,000. Finally, Rhumbline Advisers boosted its holdings in shares of Ascendis Pharma A/S by 10.3% in the 2nd quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock valued at $209,000 after purchasing an additional 143 shares in the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.